Guo Xingxian, Yang Fan, Liu Tianyi, Chen Amei, Liu Dina, Pu Jiangxia, Jia Can, Wu Yuanhong, Yuan Junfeng, Ouyang Nan, Herz Joachim, Ding Yinyuan
Centre for Lipid Research & Chongqing Key Laboratory of Metabolism on Lipid and Glucose, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Adv Sci (Weinh). 2024 Dec;11(45):e2401672. doi: 10.1002/advs.202401672. Epub 2024 Oct 15.
Low-density lipoprotein receptor-related protein-1 (LRP1) is thought to be correlated with hepatocellular carcinoma (HCC) invasion and metastasis. However, the precise mechanism through which LRP1 contributes to HCC progression remains unclear. Here, lower LRP1 levels are associated with malignant progression, and poor prognosis in patients with HCC is shown. LRP1 knockdown enhances the tumorigenicity of HCC cells in vitro and in vivo, whereas overexpression of either LRP1 or its β-chain has the opposite effect. Mechanistically, LRP1 knockdown promotes the binding of ubiquitin-like modifier 1 ligating enzyme 1 (UFL1) to OGA and accelerates ubiquitin-mediated OGA degradation, leading to increased O-GlcNAcylation of nuclear factor-kappa B (NF-κB) and subsequent inhibition of pro-apoptotic gene expression. Conversely, exogenously expressed truncated β-chain (β∆) stabilizes OGA by disrupting the association between UFL1 and OGA, consequently abolishing the anti-apoptotic effects of O-GlcNAcylated NF-κB. The findings identify LRP1, particularly its β-chain, as a novel upstream control factor that facilitates the stabilization of the OGA protein, thereby suppressing NF-κB signaling and attenuating HCC progression, thus suggesting a novel therapeutic strategy for HCC.
低密度脂蛋白受体相关蛋白1(LRP1)被认为与肝细胞癌(HCC)的侵袭和转移相关。然而,LRP1促进HCC进展的确切机制仍不清楚。在此,研究表明LRP1水平降低与恶性进展相关,且HCC患者预后不良。在体外和体内,LRP1基因敲低均增强了HCC细胞的致瘤性,而LRP1或其β链的过表达则具有相反的作用。机制上,LRP1基因敲低促进泛素样修饰物1连接酶1(UFL1)与OGA结合,并加速泛素介导的OGA降解,导致核因子-κB(NF-κB)的O-连接的N-乙酰葡糖胺化增加,进而抑制促凋亡基因表达。相反,外源性表达的截短β链(β∆)通过破坏UFL1与OGA之间的结合来稳定OGA,从而消除O-连接的N-乙酰葡糖胺化的NF-κB的抗凋亡作用。这些发现确定LRP1,尤其是其β链,是一种新型上游控制因子,可促进OGA蛋白的稳定,从而抑制NF-κB信号传导并减弱HCC进展,因此提示了一种针对HCC的新型治疗策略。